To amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have competitive access to approved drugs and licensed biological products, so as to enable eligible product developers to develop and test new products, and for other purposes.
Fair Access for Safe and Timely Generics Act of 2019 or the FAST Generics Act of 2019
This bill generally prohibits the license holder of a drug or biological product approved by the Food and Drug Administration from restricting availability of the drug or product for testing by a product developer seeking to develop a drug, generic drug, or biosimilar.
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line